Trial Profile
Clinical Trials Insight: 700054578
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2010
Price :
$35
*
At a glance
- Drugs Davunetide (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Allon Therapeutics
- 15 Mar 2010 New trial record
- 11 Mar 2010 Results reported in an Allon Therapeutics media release.